Week in Review: Active Week for China Pharma Dealmaking

Luye Pharma of Yantai will purchase the 42% of Beijing Jialin Pharma it does not already own, bringing the total price to almost $1 billion, about 24 times Jialin's 2013 profit; FortuneRock of Beijing completed a $24 million funding that it will use to advance its portfolio of novel protein drugs and prepare for an IPO; Betta Pharma of China announced a $20 million investment in Xcovery, a virtual drug developer based in Florida; WuXi PharmaTech will open a liaison office in Tel Aviv and look for investments in Israel; Janssen Pharma signed a MOU to collaborate on translational research with Shanghai Ruijin Hospital; BioChain, a US-China diagnostics company, will distribute Clinical Genomics' colorectal cancer screening technology in China; the GPCR Consortium, a new international not-for-profit effort, will characterize the structure of 200 GPCRs with the help of two China academic institutions -- the iHuman Institute at ShanghaiTech University and the Shanghai Institute of Materia Medica; Irvine Pharma Services of California is building a new CRO/CMO facility in Hangzhou; and Amerigen Pharma, a US-China company, launched its first product in China. More details.... Stock Symbols: (HK: 2186) (NYSE: WX) Share this with colleagues: // //